77
Participants
Start Date
August 14, 2012
Primary Completion Date
November 9, 2016
Study Completion Date
November 9, 2016
GTx-758 125 mg
One 125 mg tablet once a day
GTx-758 250 mg
two 125 mg tablets once daily
Urological Institute of NE New York, Albany
AMP of NY, Syracuse
AMP of NY, Oneida
UCSEPA, Bala-Cynwyd
Chesapeake Urology Research Assoc., Towson
Urology of Virginia, Virginia Beach
Carolina Clinical Trials, Concord
AMPM Research, Miami
So. Florida Medical Research, Aventura
GTx Investigative Site, St. Petersburg
Pinellas Urology, St. Petersburg
Coastal Medical Center, Sarasota
West Clinic, Memphis
The Urology Group, Cincinnati
Urology of Indiana, Greenwood
First Urology PSC, Jeffersonville
Five Valleys Urology, Missoula
Univ. of Colorado Cancer Center, Aurora
VA of Greater Los Angeles, Los Angeles
Tower Urology, Los Angeles
Urology Specialists of So. California, Torrance
Urology Associates Medical Group, Burbank
Genesis Healthcare Partners, San Diego
San Bernardino Urological Assoc., San Bernardino
Seattle Cancer Care Alliance, Univ. of Washington, Seattle
Connecticut Clinical Research Center, Middlebury
Lead Sponsor
GTx
INDUSTRY